Zuranolone: A case study in (regulatory) rush to judgement?

Area of Science:

• Drug regulatory sciences
• Pharmaceutical policy
• Clinical trial evaluation

Background:

• Sage and Biogen sought approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD).
• The US FDA approved zuranolone for PPD in August 2023 but not for MDD.
• The expedited review, including priority review and 'fast-track' designation, shortened the approval timeline significantly.

Purpose of the Study:

• To examine the clinical trial data submitted for zuranolone.
• To discuss potential shortcomings in regulatory gatekeeping due to policy shifts.
• To analyze the implications of lowered evidence thresholds for drug approval.

Main Methods:

• Review of clinical trial data for zuranolone.
• Analysis of regulatory policies impacting drug approval efficiency.
• Case study approach focusing on zuranolone's approval process.

Main Results:

• Zuranolone received FDA approval for PPD under an expedited pathway.
• The 'fast-track' designation allowed for a reduced evidence standard, focusing on surrogate outcomes.
• Concerns are raised about the balance of potential benefits versus harms for drugs approved under these conditions.

Conclusions:

• The zuranolone approval serves as a case study for evolving drug regulatory sciences.
• Policy shifts prioritizing speed and efficiency may compromise public interest by lowering evidence thresholds.
• Regulatory bodies' gatekeeping role may be weakened, necessitating critical evaluation of new drug approvals.